Abstract
The draft genomes of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) strain MM66 and MM66 isolates demonstrating altered vancomycin resistance levels were produced in an effort to provide information on mutations contributing to the vancomycin resistance levels observed in these strains.
GENOME ANNOUNCEMENT
The use of vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections (1, 2) has been challenged by the emergence of vancomycin-intermediate (3) and -resistant (4, 5) S. aureus (VISA and VRSA, respectively). We reported on a heterogeneous vancomycin-intermediate S. aureus (hVISA) strain (MM66) isolated from a hospital in Las Cruces, New Mexico, that when grown in the presence of vancomycin gave rise to stable VISA subpopulations (6). In order to provide insight on the MM66 hVISA mechanism, we have completed and compared the draft genomes of MM66, an MM66 VISA (MM66-4) (6), and a reduced vancomycin-intermediate (RVI) MM66 isolate (MM66RVI-4).
MM66RVI-4 was obtained by passaging MM66 in Luria broth (LB) and selecting for colonies unable to grow on LB agar containing 1 µg/ml vancomycin. The DNA of all strains was isolated from overnight cultures (37° C, 200 rpm) grown in Mueller-Hinton broth (MHB). Draft genomes of MM66 and MM66RVI-4 were produced with the Roche 454 GS (Junior) pyrosequencing platform and assembled using the Roche GS de novo assembler (v. 2.7). Libraries of MM66 and MM66-4 were constructed with the phusion-based Illumina genomic DNA library preparation protocol and sequenced using Illumina genome analyzer II 90-bp paired-end reads. De novo assembly was generated using filtered sequence reads and the ABySS assembler (v. 1.3.7) (7). All genome sequences were uploaded to the RAST server for annotation (8).
The vancomycin Etest MIC (6) of MM66RVI-4 and MM66 were 2 µg/ml and 3 µg/ml, respectively. MM66RVI-4 also demonstrated decreased distances grown on 0 to 3 µg/ml vancomycin (41.6 mm ± 3) and 0 to 3 µg/ml teicoplanin (16 mm ± 3) gradients (9) compared to MM66 (61.6 mm ± 4, and 30.6 mm ± 4, respectively (n = 3; P ≤ 0.05). In addition, MM66RVI-4 did not grow as well in MHB containing 2.5 µg/ml vancomycin and demonstrated reduced cell survival in vancomycin resistance population analysis (9) (0 to 3.5 µg/ml) performed with MH agar. Furthermore, whereas MM66 grew on a 0 to 175 µg/ml oxacillin gradient (84.0 mm ± 2), MM66RVI-4 grew only on a 0 to 0.5 µg/ml gradient (73 mm ± 5).
Draft genome information for all strains is summarized in Table 1. The number of RAST predicted protein-coding sequences were 2,684 (454) and 2,858 (Illumina) for MM66 and 2,563 and 2,814 for MM66RVI-4 and MM66-4, respectively. All strains sequenced were multilocus sequence type 5 (ST-5) and staphylococcal cassette chromosome mec type II (SCCmecII) (10, 11). The isolation ST-5/SCCmecII strains in the Las Cruces area have been previously reported (12, 13). The loss of oxacillin resistance in MM66RVI-4 is corroborated by an ~46.5-kb deletion of SCCmecII that remains in MM66 and MM66-4. Selection for VISA in the laboratory can also lead to SCCmec loss (14, 15). Mutations in genes encoding the two-component GraSR system are thought to support the VISA mechanism (16–19) and all MM66 derivatives harbored the same mutation in graS (S270N). In addition, mutations within apt and yycG of MM66-4 (20) were confirmed.
TABLE 1.
Staphylococcus aureus genome assembly and accession numbers
| Strain | Sequence coverage (%) | No. of contigs (bp) | N50 (Mbp) | Genome length (bp) | GC content (%) | Accession no. |
|---|---|---|---|---|---|---|
| MM66 | 30.1a | 114 (>200) | 0.17 | 2,834,320 | 32.9 | JMBT00000000 |
| MM66 | 348b | 90 (>1,000) | 0.09 | 3,002,171 | 33.0 | CCCM000000000 |
| MM66RVI-4 | 36.6a | 197 (>200) | 0.21 | 2,732,996 | 33.0 | JMBU00000000 |
| MM66-4 | 612b | 73 (>1,000) | 0.15 | 2,940,194 | 32.8 | CCCI000000000 |
454 sequence coverage.
Illumina sequence coverage.
Nucleotide sequence accession numbers.
These whole-genome shotgun projects have been deposited at DDBJ/EMBL/GenBank under the accession numbers JMBT00000000, CCCM000000000, JMBU00000000, and CCCI000000000.
ACKNOWLEDGMENTS
We thank Mitchell Nelson for isolating and characterizing MM66RVI-4. We acknowledge prior support from the National Institutes of Health (SC1GM083882-01) (to J.E.G., P20GM103451, NM-INBRE program) as well as the Oklahoma Agricultural Experimental Station.
Footnotes
Citation Matyi SA, Ramaraj T, Sundararajan A, Lindquist IE, Devitt NP, Schilkey FD, Lamichhane-Khadka R, Hoyt PR, Mudge J, Gustafson JE. 2014. Draft genomes of heterogeneous vancomycin-intermediate Staphylococcus aureus strain MM66 and MM66 derivatives with altered vancomycin resistance levels. Genome Announc. 2(4):e00688-14. doi:10.1128/genomeA.00688-14.
REFERENCES
- 1. Levine DP. 2006. Vancomycin: a history. Clin. Infect. Dis. 42(Suppl 1):S5–12. 10.1086/491709 [DOI] [PubMed] [Google Scholar]
- 2. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52:285–292. 10.1093/cid/cir034 [DOI] [PubMed] [Google Scholar]
- 3. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135–136. 10.1093/jac/40.1.135 [DOI] [PubMed] [Google Scholar]
- 4. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GR, Brown WJ, Cardo D, Fridkin SK, Vancomycin-Resistant Staphylococcus aureus Investigative Team 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342–1347. 10.1056/NEJMoa025025 [DOI] [PubMed] [Google Scholar]
- 5. Weigel LM, Clewell DB, Gill SR, Clark NC, McDougal LK, Flannagan SE, Kolonay JF, Shetty J, Killgore GE, Tenover FC. 2003. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302:1569–1571. 10.1126/science.1090956 [DOI] [PubMed] [Google Scholar]
- 6. Delgado A, Riordan JT, Lamichhane-Khadka R, Winnett DC, Jimenez J, Robinson K, O’Brien FG, Cantore SA, Gustafson JE. 2007. Hetero-vancomycin-intermediate methicillin-resistant Staphylococcus aureus isolate from a medical center in Las Cruces, New Mexico. J. Clin. Microbiol. 45:1325–1329. 10.1128/JCM.02437-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Simpson JT, Wong K, Jackman SD, Schein JE, Jones SJ, Birol I. 2009. ABySS: a parallel assembler for short read sequence data. Genome Res. 19:1117–1123. 10.1101/gr.089532.108 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O. 2008. The RAST server: rapid annotations using subsystems technology. BMC Genomics 9:75. 10.1186/1471-2164-9-75 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. O’Leary JO, Langevin MJ, Price CT, Blevins JS, Smeltzer MS, Gustafson JE. 2004. Effects of sarA inactivation on the intrinsic multidrug resistance mechanism of Staphylococcus aureus. FEMS Microbiol. Lett. 237:297–302. 10.1111/j.1574-6968.2004.tb09710.x [DOI] [PubMed] [Google Scholar]
- 10. Hiramatsu K, Cui L, Kuroda M, Ito T. 2001. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol. 9:486–493. 10.1016/S0966-842X(01)02175-8 [DOI] [PubMed] [Google Scholar]
- 11. Ito T, Katayama Y, Hiramatsu K. 1999. Cloning and nucleotide sequence determination of the entire mec DNA of pre-methicillin-resistant Staphylococcus aureus N315. Antimicrob. Agents Chemother. 43:1449–1458 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Matyi SA, Dupre JM, Johnson WL, Hoyt PR, White DG, Brody T, Odenwald WF, Gustafson JE. 2013. Isolation and characterization of Staphylococcus aureus strains from a Paso del Norte dairy. J. Dairy Sci. 96:3535–3542. 10.3168/jds.2013-6590 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. O’Brien FG, Lim TT, Winnett DC, Coombs GW, Pearson JC, Delgado A, Langevin MJ, Cantore SA, Gonzalez L, Gustafson JE. 2005. Survey of methicillin-resistant Staphylococcus aureus strains from two hospitals in El Paso, Texas. J. Clin. Microbiol. 43:2969–2972. 10.1128/JCM.43.6.2969-2972.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Adhikari RP, Scales GC, Kobayashi K, Smith JM, Berger-Bächi B, Cook GM. 2004. Vancomycin-induced deletion of the methicillin resistance gene mecA in Staphylococcus aureus. J. Antimicrob. Chemother. 54:360–363. 10.1093/jac/dkh350 [DOI] [PubMed] [Google Scholar]
- 15. Noto MJ, Fox PM, Archer GL. 2008. Spontaneous deletion of the methicillin resistance determinant, mecA, partially compensates for the fitness cost associated with high-level vancomycin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 52:1221–1229. 10.1128/AAC.01164-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Meehl M, Herbert S, Götz F, Cheung A. 2007. Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 51:2679–2689. 10.1128/AAC.00209-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Howden BP, Stinear TP, Allen DL, Johnson PD, Ward PB, Davies JK. 2008. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob. Agents Chemother. 52:3755–3762. 10.1128/AAC.01613-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Neoh HM, Cui L, Yuzawa H, Takeuchi F, Matsuo M, Hiramatsu K. 2008. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob. Agents Chemother. 52:45–53. 10.1128/AAC.00534-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Cui L, Neoh HM, Shoji M, Hiramatsu K. 2009. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 53:1231–1234. 10.1128/AAC.01173-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Multari RA, Cremers DA, Bostian ML, Dupre JM, Gustafson JE. 2013. Proof of principle for a real-time pathogen isolation media diagnostic: the use of laser-induced breakdown spectroscopy to discriminate bacterial pathogens and antimicrobial-resistant Staphylococcus aureus strains grown on blood agar. J. Pathog. 2013:2013:898106. 10.1155/2013/898106 [DOI] [PMC free article] [PubMed] [Google Scholar]
